课题基金 / 基金详情

Selectivity for Kinesin-driven Transport of Axonal RNA Granules

Selectivity for Kinesin-driven Transport of Axonal RNA Granules
驱动蛋白驱动的轴突 RNA 颗粒运输的选择性
批准号:
9791030
负责人:
Yusuke Fukuda
金额:
$10.66万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-09-30 至 2020-05-22
关键词:

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
细胞内转运对神经元整个生命周期的功能和活性至关重要。剪接因子脯氨酸- 富含谷氨酰胺(SFPQ)是一种RNA结合蛋白,包装营养调节的转录本,如Bclw, 形成RNA颗粒(RNAGs)。这些转录本的本地翻译对于保护轴突免受 退化。这项资助的目的是了解SFPQ RNAG本地化的机制 到轴突并在那里翻译。这项调查建立在我的主要发现基础上:1)SFPQ具体绑定到 KIF5A是Kinesin-1马达家族的三个成员中的一个,并且只与一个相关的Kinesin有关 轻链(KLC),KLC1;2)在卷曲线圈(CC)区域内新定义的一致EDxYxE基序 与KIF5A/KLC1结合需要SFPQ;和3)KIF5A的可变羧基末端尾部(CTT)区域是 绑定到SFPQ时需要。这些数据表明,肌动蛋白的选择性与人类高度相关 遗传性Charcot-Marie-Tooth病(CMT)中,KIF5A是唯一突变的kinesin-1马达 痉挛性截瘫(HSP)和肌萎缩侧索硬化症(ALS)。此外,SFPQ中的ALS突变存在 在与EDxYxE基序相邻的CC区域内。总之,我提出了一个中心假设,即SFPQ RNAG通过高度特异的KIF5A/KLC1依赖的运输定位于轴突,并破坏 这一途径导致了KIF5A和SFPQ相关的神经疾病。在本提案中,我将测试以下内容 这一假说的预测:1)SFPQ的顺行传输依赖于CTT介导的相互作用 2)轴突存活需要KIF5A介导的SFPQ RNAG到轴突的运输; 3)Bclw模拟物可以预防KIF5A介导的轴突转运中断所致的轴突变性。 SFPQ。这三个目标将揭示对特定动蛋白驱动的运输过程中缺陷的机械性理解 在神经系统疾病中典型地导致轴突变性,并将评估其治疗潜力 一种高度创新的Bclw多肽。我已经设计了一个有效的培训计划来执行这项建议,并 4个专业训练领域的进展:1)研究空间调节的分区神经元培养系统 蛋白质表达;2)先进的轴突活细胞定量成像技术;3)转录和 蛋白质组学分析和确定专门化运动适配器复合体形成的调控机制 选择性剪接和翻译后修饰;以及4)使用体内疾病模型进行治疗 干预。我的职业发展计划是高度协作的;几位顾问很容易 在大哈佛医学院校园的多学科环境中提供。vt.在.的基础上 结论我将朝着我的首要目标迈出第一步,了解微管缺陷是如何- 神经元的基础运输导致神经疾病;为什么特定运动部件的突变会导致 神经元的退化;并将基本的神经科学发现转化为治疗 感觉神经元和运动神经元的神经系统疾病,包括CMT、HSP和ALS。
英文摘要
Intracellular transport is critical for the function and viability of neurons throughout life. Splicing factor proline- glutamine rich (SFPQ) is an RNA-binding protein that packages trophic-regulated transcripts, such as Bclw, into RNA granules (RNAGs). Local translation of these transcripts is critical for protecting axons from degeneration. The objective of this grant is to understand the mechanism by which SFPQ RNAGs are localized to axons and translated there. This investigation builds on my key findings that: 1) SFPQ specifically binds to only one of three members of the kinesin-1 family of motors, KIF5A, and to only one of the associated kinesin light chains (KLC), KLC1; 2) a newly defined consensus EDxYxE motif within the coiled coil (CC) region of SFPQ is required for binding to KIF5A/KLC1; and 3) the variable carboxy-terminal tail (CTT) region of KIF5A is required for binding to SFPQ. These data demonstrating selectivity of the kinesins is highly relevant to human disease as KIF5A is the only kinesin-1 motor that is mutated in Charcot-Marie-Tooth disease (CMT), hereditary spastic paraplegia (HSP) and in amyotrophic lateral sclerosis (ALS). Moreover, ALS mutations in SFPQ lie within the CC region adjacent to EDxYxE motif. Together, I propose a CENTRAL HYPOTHESIS that SFPQ RNAGs are localized to axons through a highly specific KIF5A/KLC1-dependent transport and that disruption of this pathway results in KIF5A and SFPQ-related neurological diseases. In this proposal I will test the following predictions of this Hypothesis: 1) anterograde transport of SFPQ depends on interactions mediated by the CTT of KIF5A and by KLC1; 2) axonal survival requires KIF5A-mediated transport of SFPQ RNAGs to axons; and 3) Bclw mimetics can prevent axonal degeneration caused by interruption of KIF5A-mediated transport of SFPQ. These 3 Aims will reveal mechanistic understanding of how defect in specific kinesin-driven transport characteristically leads to axon degeneration in neurological disease and will assess the therapeutic potential of a highly innovative Bclw peptide. I have designed an effective training plan to execute this proposal and to advance in 4 specialized training areas: 1) compartmented neuronal culture system to study spatial regulation of protein expression; 2) advanced quantitative live cell imaging techniques in axons; 3) transcriptomics and proteomics to profile and determine regulatory mechanism of specialized motor adaptor complex formation by alternative splicing and post-translational modifications; and 4) use of in vivo disease models for therapeutic intervention. My career development plan is designed to be highly collaborative; several advisors are readily available within the multi-disciplinary environment of the greater Harvard Medical School campus. Upon conclusion I will initiate the first step towards my overarching goal in understanding how defects in microtubule- based transport in neurons lead to neurological diseases; why mutations in a specific motor component cause degeneration in neurons; and to bridge basic neuroscience discovery into new therapeutics against neurological diseases of sensory and motor neurons including CMT, HSP and ALS.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金